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Abstract Gallic acid and its esters were evaluated as enzyme
inhibitors of recombinant p-hydroxybenzoate hydroxylase
(PHBH), a NADPH-dependent flavin monooxygenase from
Pseudomonas aeruginosa. n-Dodecyl gallate (DG) (IC50 = 16
WM) and (3)-epigallocatechin-3-O-gallate (EGCG) (IC50 = 16
WM), a major component of green tea polyphenols, showed the
most potent inhibition, while product-like gallic acid did not
inhibit the enzyme significantly (IC50 s250 WM). Inhibition
kinetics revealed that both DG and EGCG inhibited PHBH in a
non-competitive manner (KI = 18.1 and 14.0 WM, respectively).
The enzyme inhibition was caused by specific binding of the
antioxidative gallate to the enzyme, and by scavenging reactive
oxygen species required for the monooxygenase reaction.
Molecular modeling predicted that EGCG binds to the enzyme
in the proximity of the FAD binding site via formation of three
hydrogen bonds. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
p-Hydroxybenzoate hydroxylase (PHBH) (EC 1.14.13.2)
from Pseudomonas sp. is a well-characterized £avin monoox-
ygenase that catalyzes the conversion of p-hydroxybenzoate
(PHB) (1) to 3,4-dihydroxybenzoate (2) [1]. PHBH is a homo-
dimer of two identical subunits with a molecular mass of 45
kDa, each containing one FAD molecule. The £avoprotein-
mediated aromatic hydroxylation is initiated by a random
sequential binding of the two substrates, PHB and NADPH,
to the £avoenzyme, and proceeds via formation of a £avin
C(4a)-hydroperoxide intermediate [2] (Fig. 1). Mechanistic
studies on enzyme kinetics, chemical transients in catalysis,
substrate and £avin analogs have been extensively performed
[1]. Further, X-ray crystallography [3,4] and site-directed mu-
tagenesis [5,6] have revealed structural details of the monoox-
ygenase reaction.
In the course of our studies on squalene epoxidase (SE) (EC
1.14.99.7), another £avoprotein monooxygenase catalyzing a
rate-limiting step of cholesterol biogenesis [7], we found that
esters of gallic acid (3,4,5-trihydroxybenzoate) (8), such as
naturally occurring (3)-epigallocatechin-3-O-gallate (EGCG)
(3) (IC50 = 0.69 WM), a major component of green tea poly-
phenol, and synthetic n-dodecyl gallate (DG) (5) (IC50 = 0.061
WM), were potent enzyme inhibitors of recombinant rat SE
[8,9]. The SE inhibition was highly selective; they did not
show signi¢cant enzyme inhibition toward other enzymes in-
volved in cholesterol biosynthesis including a cytochrome P-
450 monooxygenase, lanosterol 14K-demethylase (CYP51)
(IC50s 100 WM). From these observations, we postulated
that the potent SE inhibition was caused by speci¢c binding
of galloyl esters to the £avoenzyme, possibly in the proximity
of the FAD binding domain, and by scavenging reactive oxy-
gen species required for the monooxygenase reaction.
In this paper, we describe that the galloyl esters also showed
good inhibition toward recombinant PHBH from Pseudomo-
nas aeruginosa [10]. The amino acid sequence of P. aeruginosa
PHBH shows ca. 20% identity to that of rat SE. In particular,
the two £avoenzymes share signi¢cant sequence similarities
around the so-called GxGxxG motif (L1-sheet^K-helix^L2-
sheet folding) and GD motif, both involved in the FAD bind-
ing (Fig. 2) [11]. Further, in order to test our hypothesis, a
molecular modeling study with the published 3D crystal struc-
ture of the enzyme was also carried out.
2. Materials and methods
2.1. Cloning and expression of recombinant PHBH
The PHBH used in this study was cloned by polymerase chain
reaction (PCR) from P. aeruginosa (strain PAO1C; ATCC 15692).
The PCR was performed on the chromosomal DNA in the presence
of 5% dimethyl sulfoxide, primed by speci¢c N-terminal and C-termi-
nal primers; 5P-AGAGTTGGATCCGCAATGAAGACTCAA-3P and
5P-GAATTCCTACTCGAGTTCCTCGTA-3P, respectively, contain-
ing the BamHI and the XhoI sites, designed on the basis of the re-
ported DNA sequence (GenBank, accession number M23173) [10].
Thus, a recombinant PHBH with an additional hexahistidine tag at
the C-terminal was subcloned into the BamHI^XhoI large fragment of
expression vector pET-22b(+) (Novagen). After con¢rmation of the
sequence, the vector plasmid was transformed into Escherichia coli
BL21(DE3)pLysS. The recombinant enzyme was then expressed by
isopropyl L-D-thiogalactopyranoside induction and puri¢ed by Ni-
chelate a⁄nity chromatography according to the manufacturer’s pro-
tocol.
2.2. Enzyme inhibition assay
Inhibitors were dissolved in 10 Wl of water (EGCG) or 20% ethanol
in water (alkyl gallates), and preincubated at 25‡C for 5 min. The
assay mixture contained in a total volume of 1 ml, 50 mM Tris^
HCl, pH 8.0, the recombinant PHBH (0.02 U), 100 WM PHB, and
200 WM NADPH. The enzyme reaction was started by addition of
NADPH, and incubated at 25‡C for 10 min, which was monitored by
measuring UV absorption at 340 nm. For the inhibition kinetics, the
KI values were determined using the same conditions as described
above. The experiments were carried out in duplicate using three
concentrations of inhibitor (0, 1/2U[IC50] and 1U[IC50]). For each
inhibitor concentration, substrate was added to give four substrate
concentrations: 25, 33, 50 and 100 WM.
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2.3. Molecular modeling
The structure of PHBH was downloaded from Protein Data Bank
(identi¢cation code 1PBE) into X-PLOR (ver. 3.851). The substrate
(PHB) used for crystallization and crystallographic water molecules
were removed during modeling. The modeling methods follow stan-
dard protocols, and include minimization of the protein structure
prior to docking to accommodate hydrogen atoms not included in
the crystal structure coordinates. The ligand (EGCG) was built by
MacroModel (ver. 6.5), energy minimized using the Monte Carlo
method (MM3* force ¢eld) to energy derivatives of less than 0.1
kcal/Aî , the structure was then optimized for the CHARMM force
¢eld using parameters obtained by the calculation. The ligand was
manually docked into PHBH within 5 Aî of the C(4a) £avin isoallox-
azine ring, while monitoring docking energy to achieve a minimum
value. Energy minimization (CHARMM force ¢eld) was run for 1000
steps, followed by minimizing to the energy derivatives of less than 0.1
kcal/Aî using the conjugate gradient method (Powell algorithm). Mo-
lecular dynamics ran for 8000 iterations of 0.5 fs after 1000 steps of
equilibration (Varlet algorithm), while the distance between the gallo-
yl 3Phydroxyl group and the C(4a) £avin isoalloxazine ring, was con-
strained to be within 5 Aî . All energy minimization and molecular
dynamics were carried out at 300 K.
3. Results and discussion
Gallic acid and its esters were evaluated as enzyme inhib-
itors of recombinant P. aeruginosa PHBH whose amino acid
sequences show ca. 20% identity to that of rat SE, the £avin
monooxygenase catalyzing the rate-limiting step of the choles-
terol biosynthesis. DG (5) (IC50 = 16 WM) and EGCG (3)
(IC50 = 16 WM) showed the most potent inhibition. n-Cetyl
(C16) gallate (4) (IC50 = 25 WM) and n-octyl (C8) gallate (6)
(IC50 = 51 WM) were also good inhibitors, however, ethyl gal-
late (7) (IC50s 250 WM) and gallic acid (8) (IC50s 250 WM)
showed poor inhibition. Furthermore, as a control, N,N-di-
methyl-n-dodecyl amine (IC50s 250 WM) did not show signif-
icant inhibition. These results were in good accordance with
those obtained for recombinant rat SE, although the latter
enzyme su¡ered more potent inhibition; the reported IC50
values for EGCG and DG were 0.69 and 0.061 WM, respec-
tively [8,9]. Thus, it was again demonstrated that the hydro-
Fig. 1. Proposed mechanism of hydroxylation of PHB (1) to 3,4-dihydroxybenzoate (2).
Fig. 2. Comparison of FAD binding sequence (a) GxGxxG motif and (b) GD motif of P. aeruginosa PHBH with vertebrate (human, rat and
mouse) SE enzymes. Pro267, Arg269 and Pro293 residues, predicted to be involved in the hydrogen bond formation with EGCG, are under-
lined.
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phobicity of the alkyl side chain of the gallate molecule plays
an important role in the £avoenzyme inhibition. Inhibition
kinetics revealed that both EGCG and DG inhibited PHBH
in a non-competitive manner with KI values of 14.0 and 18.1
WM, respectively (Fig. 3), showing a large increase in a⁄nity
of the inhibitors compared to the normal substrate PHB
(KM = 41.6 WM). Further, this indicated that the binding sites
of both inhibitors are di¡erent from the PHB binding pocket.
Indeed, according to the crystal structure of Pseudomonas
£uorescens PHBH [3,4], the substrate binding pocket (143
Aî 3) is too small to fully accommodate the inhibitor molecules,
i.e. EGCG (350 Aî 3) and DG (328 Aî 3). Here it should be
noted that P. aeruginosa PHBH is almost identical in its cata-
lytic properties to P. £uorescens PHBH; there are only two
amino acid residue di¡erences, and these are both on the sur-
face of the enzyme [1]. Interestingly, P. aeruginosa PHBH was
not signi¢cantly inhibited by substrate-like (or product-like)
gallic acid. On the other hand, 2,4-dihydroxybenzoate has
been reported to be well accepted as a substrate and converted
to a mixture of 2,3,4- and 2,4,5-trihydroxybenzoate [12]. In
contrast, gallic acid no longer has high a⁄nity to the substrate
binding site of the enzyme.
As in the case of SE inhibition, we postulate that the inhi-
bition of PHBH would be caused by speci¢c binding of gallate
to the enzyme, presumably, in close proximity to the FAD
binding domain. The enzyme reaction is thought to proceed
via formation of a £avin C(4a)-hydroperoxide intermediate,
which would be trapped by the antioxidative gallate [8,9]. In
order to test this hypothesis, we used molecular modeling in
conjunction with the X-ray structure coordinates for the pub-
lished 3D structure of P. £uorescens PHBH. The modeling
methods followed standard protocols, and EGCG was man-
ually docked into PHBH so that the hydroxyl group of the
gallate was located within 5 Aî of the C(4a) isoalloxazine ring
of FAD where formation of the hydroperoxide takes place.
The obtained energy-minimized structure predicted that
EGCG indeed binds in close proximity to the FAD binding
site via the formation of three hydrogen bonds with the active
site residues between (i) the galloyl 3Q-hydroxyl group and
carbonyl oxygen of Pro293 (distance of 3.42 Aî ), (ii) the galloyl
5Q-hydroxyl group and carbonyl oxygen of Pro267 (distance
of 4.99 Aî ) and (iii) the 4P-hydroxyl group of the B-ring and
the side chain amino group of Arg269 (distance of 2.97 Aî )
(Fig. 4). Furthermore, the distance between the galloyl 3Q-
hydroxyl group and C(4a) of the £avin isoalloxazine ring
was predicted to be 4.50 Aî . During the molecular dynamics
simulation, EGCG remained at approximately the same loca-
tion as that determined in the energy-minimized structure,
therefore implicating the formation of a stable complex with
the £avin monooxygenase.
It has been reported that the £avin ring structure moves
substantially in the active site of the enzyme to enable trans-
location of substrate/product and to regulate the reduction of
the £avin by NADPH [13]. Besides scavenging the reactive
oxygen species required for the enzyme reaction, formation
of the stable complex with EGCG would also interrupt such
movement and block the interactions with the substrate and
NADPH, leading to the inactivation of the enzyme. Further,
it should be also noted that Pro267 and Pro293, the residues
thought to be involved in the hydrogen bond formation with
EGCG, are also well conserved in SE enzymes (Fig. 2), sug-
gesting that the formation of a similar complex with EGCG
may be possible. Finally, crystallization of the PHBH^EGCG
complex, which is now in progress in our laboratory, will
provide us with further detailed structural information on
the inhibition mechanism.
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Fig. 3. Lineweaver^Burk blot analysis for PHBH inhibition by (a) EGCG and (b) DG.
Fig. 4. Energy minimized structure of PHBH^FAD^EGCG com-
plex.
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